Lipid disorders

Justification of methods and goals of treatment

J. B. Braunstein, Alan Cheng, G. Cohn, M. Aggarwal, C. M. Nass, Roger S Blumenthal

Research output: Contribution to journalArticle

Abstract

Dyslipidemia is a major risk factor for coronary heart disease (CHD). While some uncertainty exists about the clinical significance of improving high-density lipoprotein cholesterol and triglyceride levels, large primary- and secondary-prevention studies aimed at lowering low-density lipoprotein cholesterol levels with statins have convincingly reduced CHD events and total mortality. Despite the strong clinical evidence and widely publicized treatment guidelines, many hyperlipidemic patients receive inadequate lipid-lowering treatment. This failure to achieve clinical treatment goals may be due to poor physician adherence to treatment guidelines, patient noncompliance, and the presence of concomitant medical conditions that modify typical hyperlipidemia management. This review considers the challenges and available strategies to optimize lipid management in patients at risk for CHD.

Original languageEnglish (US)
Pages (from-to)979-988
Number of pages10
JournalChest
Volume120
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Coronary Disease
Lipids
Guidelines
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Primary Prevention
Therapeutics
Patient Compliance
Dyslipidemias
Secondary Prevention
Hyperlipidemias
LDL Cholesterol
HDL Cholesterol
Uncertainty
Physicians
Mortality
lipoprotein triglyceride

Keywords

  • Cardiovascular risk factors
  • Coronary heart disease
  • Dyslipidemia
  • Hypercholesterolemia
  • Lipid-lowering agents
  • Statins

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Braunstein, J. B., Cheng, A., Cohn, G., Aggarwal, M., Nass, C. M., & Blumenthal, R. S. (2001). Lipid disorders: Justification of methods and goals of treatment. Chest, 120(3), 979-988. https://doi.org/10.1378/chest.120.3.979

Lipid disorders : Justification of methods and goals of treatment. / Braunstein, J. B.; Cheng, Alan; Cohn, G.; Aggarwal, M.; Nass, C. M.; Blumenthal, Roger S.

In: Chest, Vol. 120, No. 3, 2001, p. 979-988.

Research output: Contribution to journalArticle

Braunstein, JB, Cheng, A, Cohn, G, Aggarwal, M, Nass, CM & Blumenthal, RS 2001, 'Lipid disorders: Justification of methods and goals of treatment', Chest, vol. 120, no. 3, pp. 979-988. https://doi.org/10.1378/chest.120.3.979
Braunstein, J. B. ; Cheng, Alan ; Cohn, G. ; Aggarwal, M. ; Nass, C. M. ; Blumenthal, Roger S. / Lipid disorders : Justification of methods and goals of treatment. In: Chest. 2001 ; Vol. 120, No. 3. pp. 979-988.
@article{ff72e2382e794c6a9d7d277e1d521f3c,
title = "Lipid disorders: Justification of methods and goals of treatment",
abstract = "Dyslipidemia is a major risk factor for coronary heart disease (CHD). While some uncertainty exists about the clinical significance of improving high-density lipoprotein cholesterol and triglyceride levels, large primary- and secondary-prevention studies aimed at lowering low-density lipoprotein cholesterol levels with statins have convincingly reduced CHD events and total mortality. Despite the strong clinical evidence and widely publicized treatment guidelines, many hyperlipidemic patients receive inadequate lipid-lowering treatment. This failure to achieve clinical treatment goals may be due to poor physician adherence to treatment guidelines, patient noncompliance, and the presence of concomitant medical conditions that modify typical hyperlipidemia management. This review considers the challenges and available strategies to optimize lipid management in patients at risk for CHD.",
keywords = "Cardiovascular risk factors, Coronary heart disease, Dyslipidemia, Hypercholesterolemia, Lipid-lowering agents, Statins",
author = "Braunstein, {J. B.} and Alan Cheng and G. Cohn and M. Aggarwal and Nass, {C. M.} and Blumenthal, {Roger S}",
year = "2001",
doi = "10.1378/chest.120.3.979",
language = "English (US)",
volume = "120",
pages = "979--988",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Lipid disorders

T2 - Justification of methods and goals of treatment

AU - Braunstein, J. B.

AU - Cheng, Alan

AU - Cohn, G.

AU - Aggarwal, M.

AU - Nass, C. M.

AU - Blumenthal, Roger S

PY - 2001

Y1 - 2001

N2 - Dyslipidemia is a major risk factor for coronary heart disease (CHD). While some uncertainty exists about the clinical significance of improving high-density lipoprotein cholesterol and triglyceride levels, large primary- and secondary-prevention studies aimed at lowering low-density lipoprotein cholesterol levels with statins have convincingly reduced CHD events and total mortality. Despite the strong clinical evidence and widely publicized treatment guidelines, many hyperlipidemic patients receive inadequate lipid-lowering treatment. This failure to achieve clinical treatment goals may be due to poor physician adherence to treatment guidelines, patient noncompliance, and the presence of concomitant medical conditions that modify typical hyperlipidemia management. This review considers the challenges and available strategies to optimize lipid management in patients at risk for CHD.

AB - Dyslipidemia is a major risk factor for coronary heart disease (CHD). While some uncertainty exists about the clinical significance of improving high-density lipoprotein cholesterol and triglyceride levels, large primary- and secondary-prevention studies aimed at lowering low-density lipoprotein cholesterol levels with statins have convincingly reduced CHD events and total mortality. Despite the strong clinical evidence and widely publicized treatment guidelines, many hyperlipidemic patients receive inadequate lipid-lowering treatment. This failure to achieve clinical treatment goals may be due to poor physician adherence to treatment guidelines, patient noncompliance, and the presence of concomitant medical conditions that modify typical hyperlipidemia management. This review considers the challenges and available strategies to optimize lipid management in patients at risk for CHD.

KW - Cardiovascular risk factors

KW - Coronary heart disease

KW - Dyslipidemia

KW - Hypercholesterolemia

KW - Lipid-lowering agents

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=0034820571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034820571&partnerID=8YFLogxK

U2 - 10.1378/chest.120.3.979

DO - 10.1378/chest.120.3.979

M3 - Article

VL - 120

SP - 979

EP - 988

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -